Subject: Merck Accord Is Extended On Tests Related to AIDS
Date: Published: 7/15/92 (28 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Technology Brief -- Liposome Co.:
    Merck Accord Is Extended
    On Tests Related to AIDS

    Liposome Co., Princeton, N. J., said it extended its
 agreement with Merck & Co. for testing that could eventually
 lead to a vaccine against HIV, the virus that causes AIDS.  
    Terms of the collaboration, which began last August,
 weren't disclosed.  Merck is currently testing an antigen in
 association with a Liposome product, TLC A-60, to be used in
 an HIV vaccine.  The antigen was developed jointly by Merck
 and Repligen Corp. 
    A spokesman for Merck, based in Rahway, N. J., said that
 any product to come out of the venture could take
 considerable time.  "This is a very early stage of research,"
 he said.  "This is a long way from being anything of
 commercial significance."
    Liposome also said work is continuing in its venture with
 Wyeth-Ayerst Laboratories, a unit of American Home Products
 Corp., to develop a human influenza vaccine using TLC A-60.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]